TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InhaleRx Limited ( (AU:IRX) ) has issued an announcement.
InhaleRx Limited announced its quarterly activities and financial updates, highlighting significant progress in its clinical trial programs for IRX-211 and IRX-616a. The company successfully obtained ethics approval for the IRX-211 Phase 2 trial and commenced drug manufacturing, while also securing funding to accelerate development. These developments position InhaleRx to advance its clinical trials and potentially fill a gap in the market for non-opioid, inhaled treatments for breakthrough cancer pain, amidst safety concerns over existing fentanyl-based options.
More about InhaleRx Limited
InhaleRx Limited is an Australian drug development company focused on creating novel inhaled medicines. The company is currently developing two drugs: IRX-211 for breakthrough cancer pain and IRX-616a for panic disorder. Their market focus includes pioneering clinical trials for inhaled cannabinoid medications aimed at treating pain and anxiety-related conditions, with the ultimate goal of obtaining New Drug Approval from the US FDA.
Average Trading Volume: 329,510
Technical Sentiment Signal: Buy
Current Market Cap: A$8.96M
Find detailed analytics on IRX stock on TipRanks’ Stock Analysis page.